33 / 86
Study 309
: Randomized, open-label, multicenter,
phase 3 study of eribulin versus dacarbazine
in patients with leiomyosarcoma (LMS)
and adipocytic sarcoma (ADI)
P Schöffski, R Maki, A Italiano, H Gelderblom, E
Choy, G Grignani, V Camargo, S Bauer, SY Rha, S
Chawla, JY Blay, P Hohenberger, DR D’Adamo, B
Wang, B Chmielowski, A LeCesne, GD Demetri,
S Patel
Schöffski P, et al. Presented at ASCO 2015 Annual Meeting, Chicago IL, June 3-7, 2015:abstr LBA10502
Schöffski P, et al. Lancet. 2016 Apr 16;387(10028):1629-37